You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women

https://doi.org/10.1136/ebm.8.4.110

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Lancet 360, 817. IBIS investigators.. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.. ;. :. –24.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In women with an increased risk of breast cancer, does tamoxifen reduce the risk of breast cancer and what are the associated harms?

    Design

    Randomised (allocation concealed*), blinded {clinicians, patients, data collectors, outcome assessors}†,* placebo controlled trial with median follow up of 50 months.

    Setting

    Europe, Australia, and New Zealand.

    Patients

    7152 women 35–70 years of age (mean age 51 y, 49% postmenopausal) who had an increased risk of breast cancer. Exclusion criteria included previous invasive cancer, previous deep vein thrombosis or pulmonary embolism, anticoagulant use, and pregnancy. Follow up was 99.8%.

    Intervention

    Women were allocated to receive …

    View Full Text

    Footnotes

    • Sources of funding: Cancer Research UK, and National Health and Medical Research Council Australia.

    • For correspondence: Professor J Cuzick, IBIS Trials Centre, London, UK. Jack.Cuzick{at}cancer.org.uk

    • ↵* See glossary.

    • ↵† Information provided by author.